Duration of untreated psychosis and acute remission of negative symptoms in a South American first-episode psychosis cohort

Early Interv Psychiatry. 2017 Feb;11(1):77-82. doi: 10.1111/eip.12266. Epub 2015 Aug 9.

Abstract

Aim: To determine the association between duration of untreated psychosis (DUP) and symptoms remission in a hospitalized first-episode psychosis cohort.

Methods: Inpatients with a first-episode non-affective psychosis were recruited. Subjects were divided into two groups of long and short DUP using a 3-month cut-off point, and this was related to remission at 10 weeks of treatment. Multivariate analyses were performed.

Results: Fifty-five inpatients were included. There were no differences in remission rates of positive symptoms. Up to 76.5% of the patients with a short DUP (<3 months) achieved remission of negative symptoms versus 31.6% in the DUP ≥ 3 months group (P = 0.003). After controlling for relevant factors, patients with a shorter DUP were still three times more likely to achieve negative symptoms remission (HR: 3.04, 95% CI 1.2-7.5).

Conclusions: DUP is a prognostic factor that should be considered at an early stage to identify a 'high risk' subgroup of persistent negative symptoms.

Keywords: duration of untreated psychosis; early intervention; negative symptom; psychosis; schizophrenia.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Chile
  • Chronic Disease
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • Hospitalization*
  • Humans
  • Male
  • Multivariate Analysis
  • Psychiatric Status Rating Scales / statistics & numerical data*
  • Psychometrics*
  • Psychotic Disorders / diagnosis*
  • Psychotic Disorders / drug therapy*
  • Psychotic Disorders / psychology
  • Remission Induction
  • Schizophrenia / diagnosis*
  • Schizophrenia / therapy*
  • Schizophrenic Psychology*
  • Treatment Outcome
  • Young Adult

Substances

  • Antipsychotic Agents